Tesa IPA Peptide Dosage: A Guide to the Tesamorelin and Ipamorelin Blend

There is no officially established tesa ipa peptide dosage for humans. The blend sold as Tesa IPA pairs Tesamorelin with Ipamorelin, and the ranges most often cited in research summaries and user logs are roughly 1–2 mg of Tesamorelin plus 100–300 mcg of Ipamorelin, injected once daily before bed. Tesa IPA is not FDA-approved as a combination product, so every number below should be read as experimental, not prescriptive.

What Is the Tesa IPA Blend?

Tesa IPA is a shorthand name for a peptide stack that combines two growth-hormone–releasing compounds in one vial or one syringe. Tesamorelin is a stabilized analog of growth hormone–releasing hormone (GHRH), while Ipamorelin is a selective ghrelin-receptor agonist.

The two act on different receptors. Tesamorelin signals the pituitary to produce and release growth hormone, and Ipamorelin amplifies that pulse with less impact on cortisol and prolactin than older secretagogues. Because the pathways are separate, many researchers study them together rather than alone.

Tesamorelin is FDA-approved under the brand name Egrifta for reducing visceral fat in adults with HIV-associated lipodystrophy. Ipamorelin has no approved human indication, and the Tesa IPA combination itself is not FDA-approved.

Commonly Reported Tesa IPA Peptide Dosage Ranges

The figures below appear most often in research summaries, vendor protocols, and community logs. They are not clinical dosing recommendations and do not replace guidance from a licensed healthcare professional.

Component	Frequently cited range	Frequency	Typical timing
Tesamorelin	1–2 mg	Once daily	Before bed, fasted
Ipamorelin	100–300 mcg	Once or twice daily	Pre-bed, sometimes post-workout
Combined blend	1–2 mg Tesa + 100–300 mcg Ipa	Once daily	Same syringe, subcutaneous
Cycle length	8–12 weeks	Followed by a break	—

Some protocols split Ipamorelin into a morning and an evening dose while keeping Tesamorelin to the evening only. Others use a pre-mixed ratio, which is why the effective tesa peptide dosage per injection can vary widely from one product to the next.

Tesa IPA CJC Blend Dosage: What Changes With the Variant

Many vendors sell a Tesamorelin, Ipamorelin, and CJC-1295 combination, and the tesa ipa cjc blend dosage question comes up often because CJC-1295 changes the math. CJC-1295 without DAC behaves like a short-acting GHRH, similar in duration to Tesamorelin. CJC-1295 with DAC can extend growth hormone elevation for days, which raises the risk of overlapping doses.

Typical community figures for the three-part version look like this:

• Tesamorelin: 1–2 mg per injection
• Ipamorelin: 100–200 mcg per injection
• CJC-1295 (no DAC): 100–200 mcg per injection

If a blend contains CJC-1295 with DAC, most researchers limit injections to two or three per week instead of daily. It also helps to compare any three-peptide formula against the cjc 1295 ipamorelin peptide dosage, since that two-peptide version is discussed with slightly different ranges.

Timing, Injection Technique, and Cycling

Natural growth hormone release peaks during deep sleep, so evening dosing is the most common approach. Fasting for at least two hours before and 20–30 minutes after injection is often recommended, because food and insulin can blunt the growth hormone pulse.

• Inject subcutaneously into the abdomen, thigh, or upper arm.
• Rotate sites to avoid lipohypertrophy.
• Use a fresh needle and alcohol swab every time.
• Keep injections at a consistent time each day.

Cycling is debated. Some users run 8–12 weeks on and 4 weeks off, while others use 5 days on and 2 days off. No controlled trial compares these schedules, and longer continuous use may increase side effects such as water retention or joint stiffness.

Reconstitution and Storage Basics

Most Tesa IPA vials arrive lyophilized and must be reconstituted with bacteriostatic water. A common approach is to add 1–3 mL of water to a 5–10 mg vial, then calculate units on a U-100 insulin syringe.

Vial size	Water added	Approximate concentration
5 mg	2 mL	2.5 mg/mL
10 mg	2 mL	5 mg/mL
10 mg	3 mL	3.33 mg/mL

Store reconstituted peptide in the refrigerator at 2–8°C, keep it out of direct light, and avoid repeated temperature swings. A mixed vial is generally considered usable for about 2–4 weeks, but that is a rule of thumb rather than a tested standard for every product.

Safety, Side Effects, and Legal Status

Tesa IPA is a research chemical combination, and it is not approved by the FDA for human use as a blend. Buying it for personal use is not legal as a prescription-free product in the United States.

Reported side effects tied to the individual compounds include injection-site reactions, fluid retention, tingling or numbness in the hands, increased appetite, and joint pain. Tesamorelin can raise IGF-1 levels, which is one reason lab monitoring matters in clinical settings.

People with active cancer, uncontrolled diabetes, or pituitary disease are generally advised to avoid growth-hormone secretagogues. Anyone considering this class of compounds should speak with a physician and obtain baseline labs rather than rely on forum dosing.

It also helps to understand where the stack fits in a broader research context. Many people reading about GH secretagogues also study a mots-c peptide dosage protocol for metabolic research, or review a lipo-c peptide dosage chart used in fat-loss discussions. Others look into a dsip peptide injection dosage when sleep quality is the main goal. These are separate compounds with separate mechanisms, and none of them substitutes for medical care.

COMMON QUESTIONS

Frequently Asked Questions

What is a typical Tesa IPA peptide dosage?

Ranges most often cited are 1–2 mg of Tesamorelin combined with 100–300 mcg of Ipamorelin, injected once daily before bed. There is no FDA-approved dose for the blend, so these figures come from research summaries and community logs rather than controlled human trials. Individual response and product concentration can shift the effective amount by a wide margin.

Is Tesa IPA the same as CJC-1295 and Ipamorelin?

No. Tesa IPA pairs Tesamorelin with Ipamorelin, while a CJC-1295 and Ipamorelin stack uses CJC-1295 as the GHRH component instead. Some vendors sell a three-peptide blend containing all of them, and that version is usually dosed less frequently when CJC-1295 with DAC is included.

Is Tesa IPA legal or FDA-approved?

The Tesa IPA combination is not FDA-approved for human use and is sold as a research chemical. Tesamorelin alone is approved as Egrifta for HIV-associated lipodystrophy, but Ipamorelin and the blend itself have no approved human indication. Anyone using it does so outside standard medical supervision and assumes the associated risks.